← Library
Leuprolide
FDA ApprovedSince 1985
Also known as Lupron, Eligard
Function
Primary
Prostate Cancer · Endometriosis · Precocious Puberty
Mechanism
GnRH receptor agonist — paradoxical downregulation with continuous use suppresses LH/FSH → hypogonadism.
Evidence
Clinical RCT (Phase III)
Research
Phase III TAP trials
Dosing
Range
3.75–22.5 mg depot (1–6 month)
Frequency
Monthly to every 6 months
Route
Subcutaneous · Intramuscular
Cycling
Depot dosing on schedule; no cycling.
Benefits
- ·Effective androgen/estrogen suppression
- ·Tumor regression in hormone-sensitive prostate cancer
- ·Endometriosis pain control
Risks
- ·Bone density loss
- ·CV risk
- ·Hot flashes
- ·Tumor flare initially
- ·Mood effects
Contraindications
- ·Pregnancy
- ·Undiagnosed abnormal vaginal bleeding
- ·Hypersensitivity
Regulatory
FDA-Approved Rx
Functional Groups
Cited Works
- AbbVie. Lupron Depot Prescribing Information.